vs
CHAMPIONS ONCOLOGY, INC.（CSBR）与KKR Real Estate Finance Trust Inc.（KREF）财务数据对比。点击上方公司名可切换其他公司
KKR Real Estate Finance Trust Inc.的季度营收约是CHAMPIONS ONCOLOGY, INC.的1.7倍（$25.8M vs $15.0M），CHAMPIONS ONCOLOGY, INC.净利率更高（1.8% vs -101.7%，领先103.5%），CHAMPIONS ONCOLOGY, INC.同比增速更快（11.5% vs -26.6%），过去两年CHAMPIONS ONCOLOGY, INC.的营收复合增速更高（11.8% vs -18.8%）
冠军肿瘤学公司是一家成立于2007年的美国科技企业，由约翰霍普金斯大学肿瘤学家David Sidransky博士创立。该公司开发名为TumorGrafts的小鼠模型（又称小鼠化身），可用于测试多种化疗方案、靶向药物与单克隆抗体，帮助为癌症患者筛选潜在的可行治疗方案。
KKR房地产金融信托公司是全球投资机构KKR旗下的专业房地产金融平台，主要发起、收购并管理优先担保商业地产贷款组合，抵押物多为美国各地的优质机构级商业地产，通过贷款利息收入为投资者提供稳定的经风险调整后的回报。
CSBR vs KREF — 直观对比
营收规模更大
KREF
是对方的1.7倍
$15.0M
营收增速更快
CSBR
高出38.1%
-26.6%
净利率更高
CSBR
高出103.5%
-101.7%
两年增速更快
CSBR
近两年复合增速
-18.8%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $15.0M | $25.8M |
| 净利润 | $268.0K | $-26.2M |
| 毛利率 | 51.7% | — |
| 营业利润率 | 1.2% | -105.1% |
| 净利率 | 1.8% | -101.7% |
| 营收同比 | 11.5% | -26.6% |
| 净利润同比 | -63.2% | -229.6% |
| 每股收益（稀释后） | $0.02 | $-0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSBRKREF
| Q4 25 | $15.0M | $25.8M | ||
| Q3 25 | $14.0M | $25.3M | ||
| Q2 25 | $12.4M | $30.2M | ||
| Q1 25 | $17.0M | $31.3M | ||
| Q4 24 | $13.5M | $35.1M | ||
| Q3 24 | $14.1M | $37.0M | ||
| Q2 24 | $14.0M | $40.4M | ||
| Q1 24 | $12.0M | $39.1M |
净利润CSBRKREF
| Q4 25 | $268.0K | $-26.2M | ||
| Q3 25 | $-436.0K | $13.8M | ||
| Q2 25 | $-1.8M | $-29.7M | ||
| Q1 25 | $4.5M | $-4.9M | ||
| Q4 24 | $728.0K | $20.3M | ||
| Q3 24 | $1.3M | $-7.4M | ||
| Q2 24 | $-109.0K | $25.8M | ||
| Q1 24 | $-2.5M | $-3.1M |
毛利率CSBRKREF
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
营业利润率CSBRKREF
| Q4 25 | 1.2% | -105.1% | ||
| Q3 25 | -3.8% | 50.4% | ||
| Q2 25 | -16.2% | -101.3% | ||
| Q1 25 | 26.4% | -18.3% | ||
| Q4 24 | 5.4% | 55.8% | ||
| Q3 24 | 9.5% | -19.6% | ||
| Q2 24 | -1.9% | 63.3% | ||
| Q1 24 | -21.4% | -8.7% |
净利率CSBRKREF
| Q4 25 | 1.8% | -101.7% | ||
| Q3 25 | -3.1% | 54.4% | ||
| Q2 25 | -14.9% | -98.5% | ||
| Q1 25 | 26.4% | -15.5% | ||
| Q4 24 | 5.4% | 57.7% | ||
| Q3 24 | 9.3% | -20.0% | ||
| Q2 24 | -0.8% | 63.9% | ||
| Q1 24 | -21.1% | -7.9% |
每股收益（稀释后）CSBRKREF
| Q4 25 | $0.02 | $-0.49 | ||
| Q3 25 | $-0.03 | $0.12 | ||
| Q2 25 | $-0.12 | $-0.53 | ||
| Q1 25 | $0.31 | $-0.15 | ||
| Q4 24 | $0.05 | $0.22 | ||
| Q3 24 | $0.09 | $-0.19 | ||
| Q2 24 | $-0.01 | $0.29 | ||
| Q1 24 | $-0.19 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $84.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.2M | $1.2B |
| 总资产 | $30.2M | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSBRKREF
| Q4 25 | $8.5M | $84.6M | ||
| Q3 25 | $10.3M | $204.1M | ||
| Q2 25 | $9.8M | $107.7M | ||
| Q1 25 | $3.2M | $106.4M | ||
| Q4 24 | $2.8M | $104.9M | ||
| Q3 24 | $2.9M | $108.8M | ||
| Q2 24 | $2.6M | $107.2M | ||
| Q1 24 | $4.5M | $106.5M |
股东权益CSBRKREF
| Q4 25 | $4.2M | $1.2B | ||
| Q3 25 | $3.5M | $1.2B | ||
| Q2 25 | $3.8M | $1.2B | ||
| Q1 25 | $5.5M | $1.3B | ||
| Q4 24 | $681.0K | $1.3B | ||
| Q3 24 | $-332.0K | $1.4B | ||
| Q2 24 | $-1.9M | $1.4B | ||
| Q1 24 | $-2.1M | $1.4B |
总资产CSBRKREF
| Q4 25 | $30.2M | $6.5B | ||
| Q3 25 | $30.5M | $6.5B | ||
| Q2 25 | $32.3M | $6.8B | ||
| Q1 25 | $30.6M | $6.6B | ||
| Q4 24 | $25.2M | $6.4B | ||
| Q3 24 | $24.9M | $6.8B | ||
| Q2 24 | $26.1M | $7.1B | ||
| Q1 24 | $26.8M | $7.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.7M | $72.3M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | — |
| 自由现金流率自由现金流/营收 | -13.1% | — |
| 资本支出强度资本支出/营收 | 1.6% | — |
| 现金转化率经营现金流/净利润 | -6.47× | — |
| 过去12个月自由现金流最近4个季度 | $5.6M | — |
8季度趋势，按日历期对齐
经营现金流CSBRKREF
| Q4 25 | $-1.7M | $72.3M | ||
| Q3 25 | $600.0K | $18.5M | ||
| Q2 25 | $6.9M | $21.1M | ||
| Q1 25 | $490.0K | $15.9M | ||
| Q4 24 | $-283.0K | $132.6M | ||
| Q3 24 | $311.0K | $49.1M | ||
| Q2 24 | $-1.8M | $30.6M | ||
| Q1 24 | $-919.0K | $34.5M |
自由现金流CSBRKREF
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
自由现金流率CSBRKREF
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
资本支出强度CSBRKREF
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
现金转化率CSBRKREF
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | 1.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | 6.54× | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | 1.19× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
KREF
暂无分部数据
